Krakow, Poland – January 5, 2023 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel Discussion entitled “European Partners Dream Big, Make Bold Progress” on Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time. Vatnak Vat-Ho, Chief Business Officer of Ryvu, will also participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, California.
Details on the upcoming events are as follows:
- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel Discussion on “European Partners Dream Big, Make Bold Progress”
Date and Time: Wednesday, January 18, 2023, at 12:00 p.m. Eastern Time.
Participants may register at LLS TAP: European Partners Dream Big, Make Bold Progress
- 12th Annual LifeSci Partners Corporate Access Event
Date and Time: Tuesday, January 10, 2023, at the Beacon Grand Hotel, San Francisco, California.
Ryvu Therapeutics will host 1×1 investor meetings during the event.
To register, visit: LifeSci Partners Corporate Access Event 2023